Kornimate/medical-research-clean huggingface dataset:
effect of prone positioning combined with high flow oxygen therapy on oxygenation during acute respiratory failure due to covid-19

Conditions: Covid19

Summary: the main manifestation of covid-19 is acute hypoxemic respiratory failure (ahrf). in patients with ahrf, the need for invasive mechanical ventilation is associated with high mortality. prone positioning (pp) is a recommended strategy for patients with moderate to severe acute respiratory distress syndrome (ards) undergoing invasive mechanical ventilation. early pp combined with high flow oxygen therapy may benefit spontaneous breathing patients with ahrf due to covid-19 as recently reported in jiangsu. our hypothesis is that early pp combined with high flow oxygen therapy in patients with ahrf due to covid-19 improves oxygenation.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years, * admitted to icu within 72 hours, * having confirmed or highly suspected covid-19 infection (positive rt-pcr and/or computed tomography), * having acute hypoxemic respiratory failure with a \[pao2/fio2\] ratio between 100 mmhg and 300 mmhg, * having given free and informed written consent, * being affiliated with or benefiting from a social security scheme. exclusion criteria: * unable to achieve a prone position for mobility reasons, * unable to achieve a prone position due to agitation whatever the cause, * with clinical occlusive syndrome in order to limit the risk of inhalation, * having a contraindication to the use of the esophageal catheter, * having signs of respiratory distress or disturbance of consciousness requiring intubation within the next hours, * having hypercapnia indicating the use of non-invasive ventilation (pao2\> 50 mmhg), * having severe hypoxemia defined by pao2 / fio2 \<100mmhg, * ongoing pregnancy or breastfeeding, * subject to a measure for the protection of justice.
defining the sympathetic skin response of migraineurs in the facial area

Conditions: Migraine Disorders

Summary: the aim of this study is to define the sympathetic skin response of migraineurs in the facial area. this will be achieved by exposing healthy volunteers and migraine patients to various stress stimuli (pain, visual stimulation, auditory stimulation and a mathematical challenge), and recording sympathetic skin response in the facial area.


Eligibility criteria:
inclusion criteria: * healthy volunteers with no history of any kind of recurrent headache * migraine patients according to ich3 criteria * migraine patients with more than 1 attack per month exclusion criteria: * patients with other heart or neurologic diseases * patients with hearing or visual decline * patients taking medication that effects the sympathetic system (except those taking beta blockers for migraine treatment)
a multi-centre, prospective, observational study on effectiveness and safety of zoladex® (goserelin acetate implant) 10.8 mg and zoladex® (goserelin acetate implant) 3.6 mg in chinese patients with localized or locally advanced hormonal treatment -naïve prostate cancer

Conditions: Localized or Locally Advanced Prostate Cancer

Summary: this study is a multi-centre, prospective observational study. the study plans to enrol 500 patients with localized or locally advanced prostate cancer who are eligible and intended to be prescribed zoladex® (goserelin acetate implant) 10.8 mg or zoladex® (goserelin acetate implant) 3.6 mg as monotherapy or in combination with androgen blockade (cab) at 50 clinical sites in china. the effectiveness and safety data will be collected at baseline and each visit within 26 weeks after treatment of zoladex®.

androgen deprivation therapy (adt) is a standard treatment for locally advanced or metastatic prostate cancer. it is also increasingly used in patients with high-risk localized prostate cancer or in patients with prostate-specific antigen (psa) relapse after local therapy. the luteinizing hormone-releasing hormone (lhrh) agonists, such as goserelin acetate(zoladex®), have provided an effective and reversible means of suppressing androgen level. zoladex® was originally formulated as a 3.6mg depot injection. goserelin acetate 10.8-mg depot, given once every 3 months, is pharmacodynamically equivalent to 3 consecutive monthly injections of the goserelin acetate 3.6-mg depot, offers a more convenient and cost-effective dosing regimen for patients. goserelin acetate 10.8-mg depot has been available in china since 2012. however, data on the effectiveness and safety of the long-acting depot of zoladex® (goserelin acetate depot) 10.8mg specifically in a chinese population is limited. a "real-world" observational study is proposed to establish the effectiveness and safety profile of zoladex ® 10.8mg in chinese patients with localized or locally advanced prostate cancer.

Eligibility criteria:
inclusion criteria: 1. ability to provide informed consent, complete all study assessments and have complete medical record; 2. male aged 18 years and over; 3. diagnosis of localized or locally advanced prostate cancer requiring immediate hormonal therapy; 4. being prescribed zoladex ® (goserelin acetate implant) 10.8 mg or zoladex ® (goserelin acetate implant) 3.6 mg in accordance with the terms of marketing authorization as monotherapy or in combination with androgen blockade (cab); 5. more than 26 weeks' life expectancy; exclusion criteria: 1. patients who are planned to receive radiation therapy; 2. patients with hypersensitivity to lhrh, its analogues, or any components of goserelin depot; 3. previous or concurrent hormonal therapy including surgical castration, androgen blockers, oestrogen therapy, or other lhrh agonists.
impact of platinum-based cancer treatment on endothelial function

Conditions: High Blood Pressure; Cardiovascular Complication

Summary: in this research we investigate endothelial function in cancer patients who received platinum based chemotherapy.

the goal of the study is to evaluate endothelial function in patients with platinum-based versus non-platinum-based chemotherapy. endothelial function was evaluated via angioscan( the apparatus that evaluate the stiffness of vessels by pulse wave velocity) and serum levels of endothelial nitric oxide synthase (enos),endothelin1. patients with gastrointestinal, ovarian, bladder and brest cancer would be included. patients with malignancies were followed-up from 2 weeks to 3 month after start of chemotherapy, medical records and hospital databases were searched for all the patients treated with different chemotherapy treatment for any kind of cancer.

Eligibility criteria:
inclusion criteria: * subject has solid cancer * subject is expected to start chemotherapy exclusion criteria: * pregnancy and lactation * severe impaired kidney function * severe hepatic impairment * mental disease * acute myocardial infarction 28 days ago or earlier * acute cerebrovascular event 1 month ago or earlier * rhythm disturbance that complicate pulse wave velocity evaluation
implementation and evaluation of care coordination in linkage to care for hepatitis c following release from new york city jails

Conditions: Hepatitis C

Summary: this study assesses the impact of a hepatitis c care coordination program on rates of linkage to hepatitis c care following release from new york city jails. adult patients (age 18 years and above) with chronic hepatitis c infection at bellevue hospital center 19 north prison clinic from july 1, 2015 through december 31, 2016 will be offered participation in a transitional care coordination program. the rates of linkage of these individuals following release from jail will be compared to a historical cohort of adult patients with chronic hepatitis c infection at the 19 north prison clinic from january 1, 2014 through june 31, 2015.


Eligibility criteria:
inclusion criteria: * hcv infection seen in bellevue's 19n prison infectious diseases clinic. exclusion criteria: * individuals who refuse to participate in the study when approached * individuals who are unable or unwilling to sign a consent form agreeing to participate. participants must have sufficient literacy to sign their name, as written informed consent is required for study participation * individuals who are unable to successfully negotiate the use of a telephone interpreter if required * individuals who have received a sentence that extends beyond the interval of follow up (one year sentence in city jail) * individuals who will be moved upstate to prison directly from jail * individuals who die prior to discharge from rikers island
efficacy of stem cell therapy in ambulatory and non-ambulatory children with duchenne muscular dystrophy - phase 1-2

Conditions: Duchenne Muscular Dystrophy

Summary: duchenne muscular dystrophy (dmd) is a x-linked genetic disorder primarily affecting males, resulting in an absence of dystrophin which ultimately leads to progressive muscle degeneration. patients with dmd progressively lose functional abilities of movement, breath, and eventually the ability to circulate blood. currently, there is no cure for dmd, although several strategies are being tested for treatment, none have yet proven to be sufficient. children with dmd are generally divided into two groups based on severity or progression of the disease, non-ambulatory and ambulatory. ambulatory patients are capable of walking independently while non-ambulatory patients cannot walk independently.

duchenne muscular dystrophy (dmd) is a x-linked genetic disorder primarily affecting males, resulting in an absence of dystrophin which ultimately leads to progressive muscle degeneration. patients with dmd progressively lose functional abilities of movement, breath, and eventually the ability to circulate blood. currently, there is no cure for dmd, although several strategies are being tested for treatment, none have yet proven to be sufficient. children with dmd are generally divided into two groups based on severity or progression of the disease, non-ambulatory and ambulatory. ambulatory patients are capable of walking independently while non-ambulatory patients cannot walk independently. the purpose of this study is to investigate the effects of allogenic mesenchymal stem cell therapy in ambulatory and non-ambulatory children with duchenne muscular dystrophy and determine its suitability as a form of treatment.

Eligibility criteria:
inclusion criteria: * ambulatory and non-ambulatory patients diagnosed with dmd that is proven both clinically and genetically and are between 5-20 years old who need partial respiratory support daily. patients with less than or equal to stage 1 nih, cardiac, liver, and renal function. patients must also not present any indication of cancer, allergic disease, nor bleeding diathesis. exclusion criteria: * patients who require full respiratory support. patients have stage ii nih or greater, cardiac, liver, and renal function. patients present with signs of symptoms of cancer, allergic disease, or bleeding diathesis.

Keywords: duchenne muscular dystrophy neuromuscular diseases muscular dystrophy genetic diseases, x-linked musculoskeletal diseases nervous system diseases
personalised assistive devices approach for diabetic foot ulcer prevention

Conditions: Diabetic Foot Ulcer

Summary: preventing foot ulcers in people with diabetes can reduce costs and increase quality of life. despite availability of various interventions to prevent foot ulcers, recurrence rates remain high. we hypothesise that a multimodal approach incorporating a variety of orthotic interventions that matches an individual person's need can reduce ulcer recurrence with beneficial cost-effectiveness and cost-utility.


Eligibility criteria:
inclusion criteria: * diabetes mellitus type 1 or 2 * age 18 years or above * loss of protective sensation based on the presence of peripheral neuropathy * a healed plantar foot ulcer or foot amputation in the preceding 4 years until two weeks before study inclusion * in possession of custom-made orthopaedic shoes, defined as "orthopaedic shoes type a" or "orthopaedic shoes type b" , or orthopaedic provision in regular footwear (ovac), according to the dutch healthcare system * ability to provide informed consent exclusion criteria: * foot ulcer or open amputation site(s) * active charcot's neuroarthropathy * foot infection, based on criteria of the pedis classification * amputation proximal to the metatarsal bones in both feet * healed ulcer on the apex of digitus 2-5 as the only ulcer location in the past 4 years, as surgical intervention (flexor tenotomy) is a more likely and guideline-recommended treatment for such patients, rather than the multimodal care under investigation * severe illness that would make 12-months survival unlikely, based on the clinical judgment by the physician * concomitant severe physical or mental conditions that limit the ability to follow instructions for the study, based on clinical judgment

Keywords: diabetes foot ulcer prevention cost-utility
safety, tolerability and efficacy of isis-gcgrrx in type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of isis-gcgrrx in combination with metformin versus placebo + metformin


Eligibility criteria:
inclusion criteria: * male or female, age 18 to 75 * bmi greater than or equal to 25 * hba1c greater than or equal to 7.5% and less than or equal to 10.5% * type 2 diabetes mellitus and on stable dose of oral metformin * agree to conduct home-based (fasted) blood glucose testing as directed exclusion criteria: * clinically significant abnormalities in medical history or physical exam * show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results * history of renal transplantation or renal dialysis * history of liver disease * history of greater than 3 episodes of severe hypoglycemia within 6 months of screening * use of oral anti-diabetic medication other than metformin within 3 months of screening * history of diabetic ketoacidosis * any other significant illness or condition that may interfere with the patient participating or completing the study * inability or unwillingness to comply with protocol or study procedures

Keywords: type 2 diabetes mellitus t2dm
randomized study of sequential orbital radiotherapy for graves' ophthalmopathy

Conditions: Graves' Disease

Summary: objectives: i. evaluate the effects of 20 gy of external-beam radiotherapy to 1 orbit vs. the untreated orbit at 3 and 6 months after therapy in patients with graves' ophthalmopathy. ii. evaluate whether 20 gy of external-beam radiotherapy delivered to the second orbit 6 months later in the course of the disease produces effects of equal magnitude to those observed when the first orbit was treated. iii. relate the magnitude of treatment effects to the time since onset of eye symptoms. iv. evaluate whether characteristics of radiation retinopathy are present 3 years after orbital radiotherapy.

protocol outline: the posterior region of 1 orbit is irradiated over 2 weeks with supervoltage equipment. the other orbit is treated 6 months later. the sequence of therapy is randomly assigned. the untreated eye receives a simultaneous sham treatment during each radiotherapy session. patients are followed at 3, 6, 9, 12, and 36 months.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- firm diagnosis of graves' disease with normal thyroid function, i.e.: thyroid-stimulating immunoglobulin positive thyroxine 5-12.5 micrograms/dl tri-iodothyronine 80-180 nanograms/dl thyroid-stimulating hormone 0.2-8 milli-international unit (miu/l) euthyroid due to therapy acceptable ophthalmopathy meeting at least 3 of the following criteria: chemosis or lid edema lid lag, lid retraction, or restrictive lagophthalmos proptosis at least 20 mm by krahn exophthalmometry in at least 1 eye less than 4 mm discrepancy between eyes patient perception of "stare" or "bulge" extraocular muscle motion restriction in 1 or both eyes on clinical exam or by patient report of diplopia at extremes of gaze extraocular muscle enlargement on computerized tomography (previous study results acceptable) mild to moderate ophthalmopathy, i.e.: orbital pain lacrimation photophobia visual blurring or diplopia no optic neuropathy, i.e.: afferent pupillary defect impaired color vision on d-15 testing (unless congenital color perception deficiency) visual field defect impaired visual acuity no corneal ulcers --prior/concurrent therapy-- no prior external-beam radiotherapy to the head and neck at least 2 weeks since corticosteroids --patient characteristics-- no prior head and neck tumors no diabetes no pregnant women

Keywords: graves' disease thyroid disease endocrine disorders rare disease
flaxseed consumption on biochemical and quality of life in type 2 diabetes

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: the main goal of this clinical trial is to determine the effect of flaxseed added to the diet on biochemical parameters and quality of life in patients with type 2 diabetes mellitus (t2dm). the main questions it aims to answer are: * does flaxseed supplementation given to t2dm patients for 12 weeks have an effect on biochemical parameters? * does flaxseed supplementation given to t2dm patients for 12 weeks have an effect on quality of life? researchers will compare patients with t2dm consume diet added flaxseed to a control group to see if flaxseed effect on biochemical parameters and quality of life. participants will: * complete the questionnaire, record the 3-day food consumption and be taken the anthropometric measurements at the beginning and end of the study. * take diet added 30 g ground flaxseed (intervention group) or only diet (control group) every day for 12 weeks. * visit the clinic once every 4 weeks for follow-up. * report the dietary adherence and gastrointestinal symptoms on a phone call once every week.

adult individuals between the ages of 19-65, with a body mass index (bmi) between 20-35 kg/m2, using oral anti-diabetics and not using insulin will be included in the study. patients with t2dm who agree to participate in the study will be randomly assigned to the intervention or control group using the simple randomization method. participants will be followed for 12 weeks. both groups will receive diet as part of t2dm treatment. subjects in the intervention group will consume 30 g of ground flaxseed per day in addition to their diet. the participants were asked by the researchers through a face-to-face interview technique to determine their demographic characteristics (age, marital status, education level, employment status, income level, etc.), quality of life short form (sf-36) scale, international physical activity questionnaire (ipaq) and 3-day food consumption record. a survey form questioning consumption records will be applied at the baseline and end of the study. in addition, routinely monitored biochemical parameters of the patients will be recorded from the hospital system at the baseline and end of the study. anthometric measurements will be taken and recorded by the researcher in accordance with the method. the data obtained will be evaluated in the spss package program.

Eligibility criteria:
inclusion criteria: * diagnosed with t2dm by a physician * being between the ages of 19-65 * having a body mass index (bmi) between 20-35 kg/m2 * using oral anti-diabetics and not using insulin exclusion criteria: * history of gastrointestinal diseases * high consumption of nuts, flaxseeds or sesame seeds (more than one serving per day) * food allergies or intolerances * malignancies * renal failure, liver, other endocrine or inflammatory disorders * use of lipid-lowering drugs * smoking and alcohol use * being pregnant or lactating

Keywords: type 2 diabetes mellitus flaxseed quality of life glycemic control
high flow nasal oxygen therapy in pediatric hypercapnic respiratory failure during perioperative stage

Conditions: Respiratory Insufficiency

Summary: humidified high flow nasal oxygen therapy decreases dilution of the inhaled oxygen and, by matching patient's peak flow, allows accurate delivery of the set fio2 throughout the whole inspiratory phase.the purpose of this study is to determine the impact of hign-flow nasal therapy on pediatric hypercapnic respiratory failure by comparing with nasal continuous positive airway pressure.

humidified high flow nasal oxygen therapy decreases dilution of the inhaled oxygen and, by matching patient's peak flow, allows accurate delivery of the set fio2 throughout the whole inspiratory phase.the purpose of this study is to determine the impact of hign-flow nasal therapy on pediatric hypercapnic respiratory failure by comparing with nasal continuous positive airway pressure

Eligibility criteria:
inclusion criteria: 1. age ranges from 1 to 18 years 2. hypercapnic respiratory failure: pao2\ 50 mmhg 3. candidate for non-invasive respiratory support as a result of: 1. an intention to manage the patient with non-invasive (no endotracheal tube) respiratory support 2. an intention to extubate the patient being managed with intubated respiratory support to non-invasive support exclusion criteria: 1. participation in a concurrent study that prohibits the use of hhfnc 2. active air leak syndrome 3. patients with abnormalities of the upper and lower airways; such as pierre- robin, treacher-collins, goldenhar, choanal atresia or stenosis, 4. patients with significant abdominal or respiratory malformations including tracheo-esophageal fistula, intestinal atresia, omphalocele, gastroschisis, and congenital diaphragmatic hernia 5. paco2\<50mmhg
prodromal parkinsonian features in gba1 mutation carriers

Conditions: Gaucher Disease, Type 1; Healthy

Summary: objective of the trial. to define a sub-population which is at increased risk of developing parkinson, beyond the fact of carrying gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed gaucher patients and a group of healthy people who are not carriers of gaucher disease. a group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of parkinson, obtainable.

the carriers, the healthy people and the gaucher patients will undergo a number of non-invasive tests, which test the pre-parkinson signs. the tests are based on various sense tests, blood tests, measuring of blood pressure, lying and standing, ultra-sound of the brain and a neurological test (test of the nervous system and various questionnaires).

Eligibility criteria:
inclusion criteria: * willing to participate exclusion criteria: * pd patients * dementia